Robert W. Baird reissued their neutral rating on shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) in a research report report published on Tuesday. They currently have a $4.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $5.00.

A number of other equities research analysts have also weighed in on the stock. ValuEngine lowered shares of Achillion Pharmaceuticals from a sell rating to a strong sell rating in a research note on Monday, September 11th. BidaskClub raised shares of Achillion Pharmaceuticals from a strong sell rating to a sell rating in a research note on Wednesday, August 16th. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, August 11th. Maxim Group set a $7.00 target price on shares of Achillion Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 9th. Finally, Chardan Capital cut their target price on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a neutral rating on the stock in a research note on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The company presently has an average rating of Hold and an average price target of $6.50.

Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 3.70 on Tuesday. The firm’s market cap is $506.02 million. The stock’s 50 day moving average is $4.50 and its 200 day moving average is $4.20. Achillion Pharmaceuticals has a one year low of $3.15 and a one year high of $9.19.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.16). During the same quarter in the prior year, the business posted ($0.14) earnings per share. On average, analysts predict that Achillion Pharmaceuticals will post ($0.66) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/16/achillion-pharmaceuticals-inc-achn-rating-reiterated-by-robert-w-baird.html.

Several hedge funds have recently made changes to their positions in the company. EcoR1 Capital LLC bought a new stake in shares of Achillion Pharmaceuticals in the second quarter worth approximately $3,410,000. DAFNA Capital Management LLC grew its stake in shares of Achillion Pharmaceuticals by 35.6% in the second quarter. DAFNA Capital Management LLC now owns 266,500 shares of the biopharmaceutical company’s stock worth $1,223,000 after acquiring an additional 70,000 shares during the period. Janus Henderson Group PLC bought a new stake in shares of Achillion Pharmaceuticals in the second quarter worth approximately $20,778,000. QS Investors LLC grew its stake in shares of Achillion Pharmaceuticals by 36.4% in the second quarter. QS Investors LLC now owns 378,570 shares of the biopharmaceutical company’s stock worth $1,738,000 after acquiring an additional 101,018 shares during the period. Finally, Voya Investment Management LLC grew its stake in shares of Achillion Pharmaceuticals by 13.7% in the second quarter. Voya Investment Management LLC now owns 55,819 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 6,730 shares during the period. Hedge funds and other institutional investors own 74.12% of the company’s stock.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Stock Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.